183 results
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one … be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
that you can instruct the Depositary to vote your shares. In addition, the Depositary and its agents are not responsible for failing to carry out voting … intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.
Special
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
. In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us … March 2029.
We are responsible for paying all development costs incurred by the parties in carrying out the development plan.
The agreement also
20-F/A
2023 FY
EX-12.2
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
as of, and for, the periods presented in this report;
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
20-F/A
2023 FY
EX-2.1
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
shall be responsible for the routine management of the Company’s affairs within the framework of the policy set by the Board of Directors and subject
20-F/A
EX-12.1
37jja46tlro6
26 Mar 24
Annual report (foreign) (amended)
4:57pm
F-3
cqjotefa68in
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
4fuzimlfovncvzo q7
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
l2dmll120skgktr ckc
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
hygue9143gizadr5zl
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
3f7e8m6i
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-10.2
fb85c22s ij8w456kx99
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-10.3
ynnrasg
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-10.1
rbl8olf649o9vg5
21 Sep 22
Current report (foreign)
8:00am
424B5
5kfot4yl8dy3ztalbs
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
c25nu
15 Sep 22
Current report (foreign)
8:39am
20-F/A
EX-12.2
0qxrxgfwlq36lx
9 Sep 22
Annual report (foreign) (amended)
4:15pm